Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2022-12-01 00:00:00 ET · period of report 2022-11-29 · accession 0001209191-22-059242 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-01 | 2022-11-29 | NBIX | Onyia Jude | CSO | S - Sale | $121.90 | -2,331 | 2,366 | -50% | -$284.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-29 | S | D | 2,331 | $121.90 | 2,366 | D | — | — | (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $121.18 to $122.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F3) Includes an aggregate of 272 shares purchased on August 31, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |